Pfizer vaccine ruling strengthens makers' immunity to lawsuits

Share this article:
The Supreme Court bolstered a law shielding vaccine makers from injury lawsuits.

Six of the court's justices ruled against a Pennsylvania family seeking to sue Pfizer for their daughter's seizure disorder, which they allege was caused by Wyeth predecessor Lederle Laboratories' diphtheria-tetanus-pertussis vaccine, which was discontinued in 1998. The court found that the National Childhood Vaccine Injury Act of 1986, which was designed to keep pharmas from bailing out of the vaccine market by creating a no-fault system of compensation for vaccine-related injury or death, prohibited such a suit. The parents' initial claims were denied by a Federal adjudicator under the 1986 Act. They then filed suit in Pennsylvania.

Writing for the majority, Justice Antonin Scalia said: “Provided that there was proper manufacture and warning, any remaining side effects, including those resulting from design defects, are deemed to have been unavoidable.”

Justices Sonia Sotomayor and Ruth Bader Ginsburg dissented, while Justice Elena Kagan recused herself.  In her dissent, Sotomayor said the decision ignores the intent of Congress and “leaves a regulatory vacuum in which no one ensures that vaccine manufacturers adequately take account of scientific and technological advancements when designing or distributing their products.”

Pfizer hailed the decision as “a win for public health.” EVP and general counsel Amy Schulman said in a statement: “The Vaccine Act that Congress enacted nearly 25 years ago appropriately places the responsibility for determining the optimal design of life-saving childhood vaccines in the hands of expert federal agencies, not a patchwork of state tort systems.”



 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...